+

Azuma et al., 1995 - Google Patents

Acute hemolysis during cyclosporine therapy successfully treated with vitamin E

Azuma et al., 1995

Document ID
17759407040227551517
Author
Azuma E
Hirayama M
Nakano T
Nagai M
Hiratake S
Komada Y
Sakurai M
Publication year
Publication venue
Bone marrow transplantation

External Links

Snippet

The immunosuppressant cyclosporine induces acute hemolysis (hemolytic uremic syndrome) in some patients after transplantation, possibly because of its effects on the vascular endothelium. We report a case of Coombs-negative, non-immune severe hemolytic …
Continue reading at pubmed.ncbi.nlm.nih.gov (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons

Similar Documents

Publication Publication Date Title
Morozumi et al. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts
US4581010A (en) Method of immonosuppression after transplantation of cells, tissues and organs
Breimer et al. The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients
Morris et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions
EP0272091A3 (en) Delivery vehicles with amphiphile-associated active ingredient
CA2214503A1 (en) Method for treating tumors
Klintmalm et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group
Claesson et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients
Kickler The challenge of platelet alloimmunization: management and prevention
Azuma et al. Acute hemolysis during cyclosporine therapy successfully treated with vitamin E
Vanrenterghem et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients
ATA113492A (en) MULTIPLE POUCH SYSTEM FOR THE STERILE TREATMENT OF HUMAN BLOOD PRESERVES
Bunjes et al. Graft rejection by a population of primed CDw52-host T cells after in vivo/ex vivo T-depleted bone marrow transplantation
Farmer et al. Improved outcome after intestinal transplantation: an 8-year, single-center experience
DiMichele et al. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis
DK0646132T3 (en) Amino sugars, glycoproteins, processes for their preparation, drugs containing them and their use
Hardie et al. Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine+ prednisolone with cyclosporine+ azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee
DE68901172D1 (en) (-) - 2-PYRAZOLINE COMPOUND, THEIR OPTICAL UNLOCKING AND THERAPEUTIC AGENT FOR THE TREATMENT OF CEREBRAL VEGETABLE DISEASES, CONTAINING THIS COMPOUND AS AN ACTIVE INGREDIENT.
Buesa et al. Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group
Tanabe et al. ABO-incompatible living donor kidney transplantation under tacrolimus immunosuppression
Borgies et al. Interferon alpha induced and maintained complete remission in chronic granulocytic leukemia in relapse after bone marrow transplantation
Guilhot et al. The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group
Ciancio et al. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients
Millis et al. Successful use of tacrolimus for initial rejection episodes after liver transplantation
Ishibashi et al. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载